Intuitive Surgical (NASDAQ:ISRG) Trading Down 0.4% After Insider Selling

Intuitive Surgical, Inc. (NASDAQ:ISRG) shares traded down 0.4% during mid-day trading on Wednesday after an insider sold shares in the company. The stock traded as low as $569.49 and last traded at $571.69. 353,321 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 1,947,027 shares. The stock had previously closed at $574.14.

Specifically, Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the sale, the director now directly owns 12,275 shares of the company’s stock, valued at $6,955,015. The trade was a 27.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Analyst Ratings Changes

ISRG has been the subject of a number of research reports. Bernstein Bank boosted their price target on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a report on Monday. Citigroup upped their target price on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Raymond James raised their price target on Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Mizuho upped their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Finally, Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Stock Performance

The company has a market capitalization of $203.76 billion, a price-to-earnings ratio of 91.91, a PEG ratio of 5.19 and a beta of 1.39. The business’s 50 day moving average is $548.70 and its 200 day moving average is $507.04.

Institutional Investors Weigh In On Intuitive Surgical

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bennett Selby Investments LP raised its stake in Intuitive Surgical by 3.9% in the 4th quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 17 shares during the last quarter. LVW Advisors LLC raised its stake in shares of Intuitive Surgical by 1.3% in the fourth quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider’s stock worth $756,000 after purchasing an additional 19 shares during the last quarter. Wesbanco Bank Inc. lifted its holdings in shares of Intuitive Surgical by 1.6% during the fourth quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider’s stock worth $635,000 after purchasing an additional 19 shares during the period. FSM Wealth Advisors LLC boosted its position in Intuitive Surgical by 3.7% in the fourth quarter. FSM Wealth Advisors LLC now owns 526 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 19 shares during the last quarter. Finally, Journey Strategic Wealth LLC increased its holdings in Intuitive Surgical by 1.9% in the 4th quarter. Journey Strategic Wealth LLC now owns 1,039 shares of the medical equipment provider’s stock worth $542,000 after buying an additional 19 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.